Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.

Anito-cel, a BCMA CAR T-cell therapy with a synthetic d-domain binder, achieved a 100% response rate and 79% complete responses in heavily pretreated multiple myeloma patients.

• Why it matters: Effective treatments for relapsed or refractory multiple myeloma are limited, especially after multiple prior therapies, making new options critical for improving patient outcomes.
• What they did: A phase 1 trial evaluated safety and efficacy in 38 patients receiving two dose levels of anito-cel, assessing adverse events, cytokine release syndrome, neurotoxicity, and response durability over a median follow-up of 38.1 months.
• The result: The therapy demonstrated high response rates with manageable side effects, including rare severe neurotoxicity, and enabled median progression-free survival of over 30 months, supporting further development.